Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Press Release

New results published support masitinib’s potential mode of action in Alzheimer’s Disease


8 July 2020
AB Science SA today announced the publication of preclinical study results with masitinib in Alzheimer’s disease entitled, ‘Effects of chronic masitinib treatment in APPPS1dE9 transgenic mice modeling Alzheimer’s disease’.
Preliminary version of the article in the journal "Journal of Alzheimers’s Disease" >

Masitinib given orally as an adjunct therapy has previously been reported to slow down cognitive decline in patients with Alzheimer’s disease  and a multicenter phase III study was subsequently initiated in patients with mild to moderate Alzheimer’s disease (NCT01872598).

The current research provides evidence suggesting that masitinib’s therapeutic efficacy is associated with a synapto-protective action in relation with mast cells inhibition.

Dr Benoît Delatour, Principal Investigator of the Alzheimer’s and Prion Diseases team at the ICM (Paris Brain Institute, France) and senior author of the paper said, “This research has shown that masitinib can restore normal spatial learning performance in an animal model of Alzheimer’s disease and also promotes synaptic recovery.  As such, these findings link the previously reported positive proof-of-concept clinical data for masitinib in Alzheimer’s disease with evidence of a hitherto unknown synapto-toxic mechanism associated with mast cells that can be therapeutically targeted by masitinib”.

Olivier  Hermine  (President  of  the  Scientific  Committee  of  AB  Science  and  member  of  the  Académie  des Sciences  in  France) commented, “These  data  suggest  a  novel  mechanism  by  which  masitinib  exerts  a neuroprotective  effect  in  Alzheimer’s  disease.  Overall, these results provide a new compelling biological rationale for the use of masitinib in the treatment of Alzheimer’s disease”.

Contact

AB Science

AB Science
Financial communication and press relations
investors@ab-science.com

Article posted on 8 July 2020

Share
With support